6 stories mentioning HKG:1952Updated 41m ago
Every FINWIRES story that references HKG:1952, newest first.
Everest Medicines (HKG:1952) entered into a commercialization agreement with Hainan Herui Pharmaceutical for budesonide enteric capsules, according to a Wednesday Hong Kong bourse filing.Under the agreement, Everest will commercialize the product in mainland China and provide technical guidance and quality oversight for Hainan Herui's manufacturing and supply processes.
Everest Medicines' (HKG:1952) honorary chairman and substantial shareholder, Wei Fu, increased his stake in the company via the purchase of shares, according to a Tuesday filing with the Hong Kong bourse.The 679,000 shares were acquired from the open market from June 8 to June 9 for about HK$18.9 million at an average price of about HK$27.90 apiece.
Everest Medicines (HKG:1952) said it agreed to acquire a license to Corxel Pharmaceuticals' eye drop LNZ100 for the greater China region, according to a Monday filing with the Hong Kong bourse.The firm said it would make an upfront payment for the license, as well as milestone payouts and royalties on the sales of the presbyopia treatment.The drug is already approved in the U.S. and is expected to receive Chinese regulatory nod in the first quarter of 2027.
Everest Medicines' (HKG:1952) honorary chairman and substantial shareholder, Wei Fu, increased his stake in the company via the purchase of shares, according to a Thursday filing with the Hong Kong bourse.The 690,000 shares were acquired from the open market on June 3 for about HK$20 million at an average price of about HK$28.93 apiece.
Everest Medicines (HKG:1952) unit Everest Medicines (Singapore) entered into an exclusive agreement to provide an exclusive worldwide license to Travere Therapeutics to develop and commercialize civorebrutinib, according to a Tuesday Hong Kong bourse filing.Travere Therapeutics can commercialize the drug globally except in Greater China and certain countries in East and Southeast Asia.Everest Medicines (Singapore) will receive an upfront payment of $112.5 million under the deal and up to $1.03 billion in development, regulatory, and commercial milestone payments across a maximum of five indications, alongside tiered royalties.Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases.
Everest Medicines' (HKG:1952) honorary chairman and substantial shareholder, Wei Fu, increased his stake in the company, according to a Friday Hong Kong bourse filing.The 660,000 shares were acquired from the open market on May 14 for about HK$20.7 million at an average price of about HK$31.25 apiece.
